Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Markus A Thaler"'
Autor:
Markus A Thaler, Andreas Bietenbeck, Udo Steigerwald, Thomas Büttner, Peter Schierack, Edelgard Lindhoff-Last, Dirk Roggenbuck, Peter B Luppa
Publikováno v:
PLoS ONE, Vol 14, Iss 7, p e0220033 (2019)
BackgroundPersistent antiphospholipid antibodies (aPL) constitute the serological hallmark of the antiphospholipid syndrome (APS). Recently, various new assay technologies for the detection of aPL better suited to multiplex reaction environments than
Externí odkaz:
https://doaj.org/article/44528644c64a41ad8d681c56523a4c53
Publikováno v:
Clinical Chemistry and Laboratory Medicine (CCLM). 61:1255-1265
Objectives The therapeutic antibody infliximab (IFX) has improved the life quality of numerous autoinflammatory disease patients. However, IFX can trigger the generation of anti-drug antibodies (ADA), whose optimal evaluation and management are curre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d1e3c982e4928119e1c0fa159da9fe5d
https://doi.org/10.1515/cclm-2022-0949
https://doi.org/10.1515/cclm-2022-0949
Autor:
Markus Alexander Thaler, Regina Feurer, Christoph Thaler, Natalie Sonntag, Michael Schleef, Ina-Christine Rondak, Holger Poppert
Publikováno v:
PLoS ONE, Vol 11, Iss 8, p e0160382 (2016)
Activated protein C (APC) resistance is the most common inherited prothrombotic disorder. The role of APC resistance in ischemic stroke is controversially discussed.The aim of this single center follow up study was to investigate the effect of APC re
Externí odkaz:
https://doaj.org/article/c87f5f287166479bb5f6a7c9f742550f
Autor:
Markus A, Thaler, Andreas, Bietenbeck, Udo, Steigerwald, Thomas, Büttner, Peter, Schierack, Edelgard, Lindhoff-Last, Dirk, Roggenbuck, Peter B, Luppa
Publikováno v:
PLoS ONE, Vol 14, Iss 7, p e0220033 (2019)
PLoS ONE
PLoS ONE
BackgroundPersistent antiphospholipid antibodies (aPL) constitute the serological hallmark of the antiphospholipid syndrome (APS). Recently, various new assay technologies for the detection of aPL better suited to multiplex reaction environments than
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::44ba4720d519bb8d523f882f7a7adef6
http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/50499
http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/50499
Autor:
Melina K. Grasmeier, Anna F. Langmann, Peter Langmann, Matthias Treiber, Markus A. Thaler, Peter B. Luppa
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Background: Antibodies to infliximab (ATI) in serum are associated with secondary loss of response (LOR) to infliximab (IFX) therapy in patients with inflammatory bowel disease (IBD). However, feasible ATI-related predictors of therapy success are la
Externí odkaz:
https://doaj.org/article/2a752b3c17864cdf8a98722fd95e6822